Health Care • Biotechnology: Pharmaceutical Preparations
$25.30 ▲ +0.33
(+1.32%)
MKT CAP: $1.75B • VOL: 1.71M
52W L $9 52W H $52
ROARABLE / RQD
D+ • 52/100
PIOTROSKI
4 / 9
QURE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$185.3M | -$184.3M | -$282.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$199.0M | -$239.6M | -$308.5M |
| EBITDA (Normalized) | -$185.0M | -$181.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$178.0M | -$182.7M | -$145.9M |
| Capital Expenditures (CapEx) | $439.0K | $3.4M | — |
| Free Cash Flow (FCF) | -$178.4M | -$186.1M | -$145.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $80.2M | $158.9M | — |
| Total Debt (Short + Long Term) | $49.7M | $51.3M | — |
| Total Stockholders' Equity | $198.9M | -$6.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR QURE.